United States - English - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram hbr is indicated for the treatment of depression. the efficacy of citalopram hbr in the treatment of depression was established in 4-6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation.the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. the efficacy of citalo

United States - English - NLM (National Library of Medicine)

medvantx, inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram hbr is indicated for the treatment of depression. the efficacy of citalopram hbr in the treatment of depression was established in 4-6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. the efficacy of citalopram in maint

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram tablets are indicated for the treatment of major depressive disorder (mdd) in adults [see clinical studies ( 14)] . the maxium recommended dosage of citalopram tablets when used concomitantly with a cyp2c19 inhibitor is 20 mg once daily [see warnings and precautions ( 5.2), drug interactions ( 7)] . citalopram tablets are contraindicated in patients: • taking, or within 14 days of stopping, maois (including maois such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome [see warnings and precautions ( 5.3), drug interactions ( 7)] . • taking pimozide because of risk of qt prolongation [see drug interactions ( 7)] . • with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. reactions have included angioedema and anaphylaxis [see adverse reactions ( 6.2)] . the safety and effectiveness of citalopram have not

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram tablets are indicated for the treatment of major depressive disorder (mdd) in adults [see clinical studies ( 14)] . the maxium recommended dosage of citalopram tablets when used concomitantly with a cyp2c19 inhibitor is 20 mg once daily [see warnings and precautions ( 5.2), drug interactions ( 7)] . citalopram tablets are contraindicated in patients: • taking, or within 14 days of stopping, maois (including maois such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome [see warnings and precautions ( 5.3), drug interactions ( 7)] . • taking pimozide because of risk of qt prolongation [see drug interactions ( 7)] . • with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. reactions have included angioedema and anaphylaxis [see adverse reactions ( 6.2)] . the safety and effectiveness of citalopram have not

United States - English - NLM (National Library of Medicine)

proficient rx lp - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram tablets are indicated for the treatment of major depressive disorder (mdd) in adults [see clinical studies ( 14)] . the maxium recommended dosage of citalopram tablets when used concomitantly with a cyp2c19 inhibitor is 20 mg once daily [see warnings and precautions ( 5.2), drug interactions ( 7)] . citalopram tablets are contraindicated in patients: • taking, or within 14 days of stopping, maois (including maois such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome [see warnings and precautions ( 5.3), drug interactions ( 7)] . • taking pimozide because of risk of qt prolongation [see drug interactions ( 7)] . • with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. reac

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram hbr is indicated for the treatment of depression. the efficacy of citalopram hbr in the treatment of depression was established in 4-6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. the efficacy of citalopram in maint

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram, is indicated for the treatment of depression. the efficacy of citalopram hydrobromide, in the treatment of depression was established in 4 to 6 week, controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - citalopram hydrobromide, quantity: 49.96 mg (equivalent: citalopram, qty 40 mg) - tablet, film coated - excipient ingredients: copovidone; microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; magnesium stearate; purified water; maize starch; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - citalopram hydrobromide -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - citalopram hydrobromide, quantity: 24.98 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; copovidone; microcrystalline cellulose; purified water; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for treatment of major depression